阿斯利康高血压新药III期成功

Core Insights - AstraZeneca's investigational drug Baxdrostat has achieved positive results in the Phase III clinical trial BaxHTN for patients with uncontrolled or resistant hypertension [1] - The trial demonstrated statistically and clinically significant reductions in seated systolic blood pressure (SBP) at 12 weeks with two doses (2 mg and 1 mg) of Baxdrostat compared to placebo [1] - All primary and secondary endpoints of the trial were successfully met, indicating the drug's potential effectiveness [1]